Gilead data lends insight into transforming HIV prevention landscape
European Pharmaceutical Review
NOVEMBER 13, 2024
Lenacapavir for PrEP was granted Breakthrough Therapy Designation by the US Food and Drug Administration (FDA) in October. This newly released data was presented at the International Congress on Drug Therapy in HIV Infection (HIV Glasgow) and will be published in The New England Journal of Medicine.
Let's personalize your content